AZN vs GEHC

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

GEHC presents a stark contrast between analyst optimism and deterministic fundamental health. The Piotroski F-Score of 3/9 indicates weak financial health, and the current price of $72.91 trades at a significant premium to both the Graham Number ($48.02) and the Intrinsic Value ($31.50). While the company maintains strong ROE (22.38%) and consistent earnings beats, the negative YoY earnings growth (-17.70%) and bearish technical trend suggest a period of instability. The stock is fundamentally overvalued based on deterministic models, though it remains cheaper than the broader healthcare sector average P/E.